고정 헤더 영역
상세 컨텐츠
본문
On November 2, 2013, the company was divided into Chong Kun Dang Holdings, a subsidiary in charge of the investment business division, and Chong Kun Dang, a new company in charge of the pharmaceutical business division.
On December 6, 2013, it was re-listed on the Korea Exchange's securities market.
It has excellent development capability for new and improved new drugs and generic drugs, and conducts research and development investments of more than 10% of annual sales, and is in the process of developing new drugs such as targeted anti-cancer drugs and autoimmune diseases.
2020/08/06 - [KOSPI] - LIG Nex1 leads defense industry by developing military drone motors
2020/07/30 - [KOSPI] - Woori Financial Group to support 10 trillion won in Korean New Deal
2020/07/28 - [KOSPI] - Corona Vaccine SK Chemicals is getting more attention with Bill Gates letter
'기타' 카테고리의 다른 글
| Seoul Viosys boasting COVID-19 sterilization UV LED technology (0) | 2020.08.12 |
|---|---|
| Generation of rapid in vitro diagnostic medical devices (0) | 2020.08.11 |
| Steering, Mando leading chassis as auto parts manufacturer (0) | 2020.08.09 |
| Samsung C&T floating in Banpo Jugong 1st Complex (0) | 2020.08.08 |
| As a subsidiary of Chong Kun Dang, Kyung-Dang Ahn also has excellent financial statements. (0) | 2020.08.07 |
댓글 영역